Otonomy Announces Exclusive License Agreement with Kyorin for Novel Compound in OTO-6XX Hearing Loss ProgramGlobeNewsWire • 08/03/20
Otonomy to Report Second Quarter 2020 Financial Results and Provide Corporate UpdateGlobeNewsWire • 07/28/20
Otonomy Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesGlobeNewsWire • 07/13/20
Otonomy Reports Positive Top-Line Results from Phase 1/2 Clinical Trial of OTO-313 in Patients with TinnitusGlobeNewsWire • 07/06/20
Otonomy Reports First Quarter 2020 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/07/20
Otonomy's (OTIC) CEO David Weber on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 02/28/20
Do Options Traders Know Something About Otonomy (OTIC) Stock We Don't?Zacks Investment Research • 02/21/20
Otonomy Presents Preclinical Results for GJB2 Gene Therapy Collaboration and Cisplatin Otoprotection ProgramGlobeNewsWire • 01/28/20
Otonomy's (OTIC) CEO David Weber on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/06/19
Analysts Estimate Otonomy (OTIC) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 10/28/19
AGTC and Otonomy Announce Strategic Collaboration to Develop and Commercialize Gene Therapy for Congenital Hearing LossGlobeNewsWire • 10/01/19